source
- J&J touts Icotyde prescriptions, but not sales, in first full quarterJohnson & Johnson teased some details on Wednesday morning about how the launch of its expected blockbuster Icotyde performed in the second quarter. Without disclosing how much revenue the plaque p…Endpoints · 14d ago↗ source
- Nava Therapeutics emerges with $89M for lipid nanoparticlesNava Therapeutics, a secretive startup that’s been working on a new generation of lipid nanoparticles that target the bone marrow, immune cells and the kidney, has raised $89 million, the company t…Endpoints · 14d ago↗ source
- Braveheart files for IPO to fund Phase 3 of Hengrui's Cytokinetics rivalBiotechs are sprinting to the IPO queue. In the industry's fourth IPO filing in two weeks, Braveheart Bio is seeking a Nasdaq listing to fuel Phase 3 testing of a cardio drug that could potentially…